| [1] |
SMOLARZ B, BIERNACKA K, ŁUKASIEWICZ H, et al. Ovarian cancer-epidemiology, classification, pathogenesis, treatment, and estrogen receptors' molecular backgrounds[J]. Int J Mol Sci, 2025, 26(10): 4611. doi:10.3390/ijms26104611
doi: 10.3390/ijms26104611
|
| [2] |
KORDOWITZKI P, LANGE B, ELIAS K M, et al. Transforming treatment paradigms: focus on personalized medicine for high-grade serous ovarian cancer[J]. CA: A Cancer J Clin, 2025, 75(5): 436-460. doi:10.3322/caac.70008
doi: 10.3322/caac.70008
|
| [3] |
KONSTANTINOPOULOS P A, MATULONIS U A. Clinical and translational advances in ovarian cancer therapy[J]. Nat Cancer, 2023, 4(9): 1239-1257. doi:10.1038/s43018-023-00617-9
doi: 10.1038/s43018-023-00617-9
|
| [4] |
DENG T, LIU K, CHEN L, et al. A prospective randomized multicenter trial for lymphadenectomy in early-stage ovarian cancer: LOVE study[J]. J Gynecol Oncol, 2023, 34(3): e52. doi:10.3802/jgo.2023.34.e52
doi: 10.3802/jgo.2023.34.e52
|
| [5] |
WANG H, WANG S, WANG P, et al. Survival outcomes of lymph node dissection in early-stage epithelial ovarian cancer: Identifying suitable candidates[J]. World J Surg Oncol, 2024, 22(1): 294. doi:10.1186/s12957-024-03571-7
doi: 10.1186/s12957-024-03571-7
|
| [6] |
LU Y, YE M, MA D, et al. Number of resected lymph nodes and survival status in node-negative esophageal squamous cell carcinoma: A cohort study[J]. Int J Gen Med, 2024, 17: 4633-4643. doi:10.2147/ijgm.s480893
doi: 10.2147/ijgm.s480893
|
| [7] |
BAHARDOUST M, YARAHMADI D, NIROOMAND B, et al. Effect of the number of negative lymph nodes removed on the survival and recurrence rate patients with non-small-cell lung cancer undergoing surgery: A multicenter retrospective cohort study[J]. Medicine, 2025, 104(18): e42402. doi:10.1097/md.0000000000042402
doi: 10.1097/md.0000000000042402
|
| [8] |
RAHIMPOUR E, NIROOMAND B, KALATEHJARI M, et al. Effect of the number of negative lymph nodes removed on the survival and recurrence rate after primary surgery in patients with ovarian cancer: A multi-center retrospective cohort study[J]. Indian J Surg Oncol, 2025, 16(2): 536-542. doi:10.1007/s13193-024-02077-8
doi: 10.1007/s13193-024-02077-8
|
| [9] |
PRAT J, D'ANGELO E, ESPINOSA I. Ovarian carcinomas: Clinicopathologic and molecular features with comments on 2014 FIGO staging[J]. Am J Surg Pathol, 2025, 49(4): e1-e14. doi:10.1097/pas.0000000000002352
doi: 10.1097/pas.0000000000002352
|
| [10] |
CHARLSON M E, CARROZZINO D, GUIDI J, et al. Charlson comorbidity index: a critical review of clinimetric properties[J]. Psychother Psychosomat, 2022, 91(1): 8-35. doi:10.1159/000521288
doi: 10.1159/000521288
|
| [11] |
ABBASSI F, PFISTER M, LUCAS K L, et al. Milestones in surgical complication reporting: Clavien-Dindo classification 20 years and comprehensive complication index 10 years[J]. Annal Surg, 2024, 280(5): 763-771. doi:10.1097/sla.0000000000006471
doi: 10.1097/sla.0000000000006471
|
| [12] |
黄山高, 吴月玲, 张颖. 瞄准未来: 卵巢癌靶向治疗的新进展[J]. 实用医学杂志, 2024, 40(14): 1901-1907.
|
| [13] |
李璡, 温灏, 刘淑娟, 等. 2023年中国卵巢癌诊疗现状白皮书[J]. 中国实用妇科与产科杂志, 2023, 39(12): 1225-1232.
|
| [14] |
赵虹琳, 李婷婷, 丁国武. 1990-2019年中国女性卵巢癌疾病负担趋势分析[J]. 中华肿瘤防治杂志, 2023, 30(9): 507-512.
|
| [15] |
KUHN W, TATO VAREIA S, HOUSHEIMI A EL, et al. Prognosis and therapy of ovarian cancer: Part 2-the shifting landscape of medical treatment in ovarian cancer[J]. Oncol Res Treat, 2025, 48(10): 643-654. doi:10.1159/000546245
doi: 10.1159/000546245
|
| [16] |
LAVEN P, WENZEL H H B, VAN DER AA M A, et al. Impact of lymph node dissection and adjuvant chemotherapy on survival of patients with early-stage ovarian cancer: Update of a national cohort study[J]. Gynecol Oncol, 2025, 200: 51-57. doi:10.1016/j.ygyno.2025.07.010
doi: 10.1016/j.ygyno.2025.07.010
|
| [17] |
BAO R, OLIVIER M, XIANG J, et al. The significance of lymph node dissection in patients with early epithelial ovarian cancer[J]. Annal Ital Di Chirurgia, 2024, 95(4): 628-635. doi:10.62713/aic.3353
doi: 10.62713/aic.3353
|
| [18] |
WIMBERGER P, PFISTERER J, DU BOIS A, et al. Impact of lymphadenectomy rates in the quality assurance program in early ovarian cancer of the AGO Study Group-real-world observations[J]. Eur J Surg Oncol, 2025, 51(6): 109696. doi:10.1016/j.ejso.2025.109696
doi: 10.1016/j.ejso.2025.109696
|
| [19] |
KARADAĞ İ, KARAKAYA S. Ideal lymph node number for ovarian malignancies[J]. Cureus, 2022, 14(1): e20869.
|
| [20] |
HEIKKINEN J, KÄRKKÄINEN H, ELORANTA M L, et al. Postoperative complications of upfront ovarian cancer surgery and their effects on chemotherapy delay[J]. Curr Oncol, 2024, 31(9): 5630-5642. doi:10.3390/curroncol31090417
doi: 10.3390/curroncol31090417
|
| [21] |
KUUSELA K, NORPPA N, AURANEN A, et al. Maximal surgical effort increases the risk of postoperative complications in the treatment of advanced ovarian cancer[J]. Eur J Surg Oncol, 2022, 48(12): 2525-2530. doi:10.1016/j.ejso.2022.06.007
doi: 10.1016/j.ejso.2022.06.007
|
| [22] |
CHEN J, GUO Y, LI H, et al. Near-infrared dye-labeled antibody COC183B2 enables detection of tiny metastatic ovarian cancer and optimizes fluorescence-guided surgery[J]. J Surg Oncol, 2020, 122(6): 1207-1217. doi:10.1002/jso.26130
doi: 10.1002/jso.26130
|
| [23] |
SASSINE D, LIU C, SONODA Y, et al. Safety and Efficacy of Supradiaphragmatic Lymph Node Dissection in Advanced Ovarian Cancer[J]. J Gynecol Surg, 2022, 38(3): 202-206. doi:10.1089/gyn.2022.0030
doi: 10.1089/gyn.2022.0030
|
| [24] |
BLANC-DURAND F, CLEMENCE WEI XIAN L, TAN D S P. Targeting the immune microenvironment for ovarian cancer therapy[J]. Front Immunol, 2023, 14: 1328651. doi:10.3389/fimmu.2023.1328651
doi: 10.3389/fimmu.2023.1328651
|
| [25] |
JAZWINSKA D E, KULAWIEC D G, ZERVANTONAKIS I K. Cancer-mesothelial and cancer-macrophage interactions in the ovarian cancer microenvironment[J]. Am J Physiol Cell Physiol, 2023, 325(3): C721-C730. doi:10.1152/ajpcell.00461.2022
doi: 10.1152/ajpcell.00461.2022
|
| [26] |
PENG J M, SU Y L. Lymph node metastasis and tumor-educated immune tolerance: Potential therapeutic targets against distant metastasis[J]. Biochem Pharmacol, 2023, 215: 115731. doi:10.1016/j.bcp.2023.115731
doi: 10.1016/j.bcp.2023.115731
|
| [27] |
ALSALMAN A, AL-MTERIN M A, MURSHED K, et al. Circulating and Tumor-Infiltrating Immune Checkpoint-Expressing CD8+ Treg/T Cell Subsets and Their Associations with Disease-Free Survival in Colorectal Cancer Patients[J]. Cancer, 2022, 14(13): 3194. doi:10.3390/cancers14133194
doi: 10.3390/cancers14133194
|
| [28] |
FAHIM M I, ALI A M, ALLAM R M. Impact of Lymph Node Sampling in Stage II and III Epithelial Ovarian Cancer Patients with Clinically Negative Lymph Nodes[J]. Indian J Surg Oncol, 2020, 11(2): 196-200. doi:10.1007/s13193-019-01013-5
doi: 10.1007/s13193-019-01013-5
|
| [29] |
ESEN B, SEYMEN H, ARMUTLU A, et al. Impact of Pelvic Lymph Node Dissection on Early Oncological Outcomes in Intermediate-Risk Prostate Cancer Patients With Node-Negative PSMA PET[J]. Prostate, 2025, 85(8): 777-783. doi:10.1002/pros.24884
doi: 10.1002/pros.24884
|
| [30] |
李剑琦,生秀杰.长链非编码RNA LINC00467在卵巢癌的表达及其临床意义[J].实用医学杂志, 2022, 38,(12):1486-1493.
|